Menu
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, in in vivo mouse and hamster models, highly potent viral neutralizing activity, protection against infection by SARS-COV-2 and minimized development of alveolar [lung] damage, for XVR011, its unique Llama-derived VHH72-Fc antibody for potential treatment and prevention of Covid-19.
